The monopoly is over, but the real competition is just beginning.
Quando uma patente expira, não se trata apenas de uma mudança jurídica — trata-se de uma redistribuição de poder sobre quem pode acessar o alívio que a medicina promete. No Brasil, a aprovação do Ozivy pela Anvisa em maio de 2026 marca o fim do monopólio da Novo Nordisk sobre a semaglutida, abrindo caminho para que fabricantes nacionais disputem um mercado que combina necessidade médica genuína, fenômeno cultural e bilhões em receita. A EMS tornou-se a primeira empresa brasileira a cruzar esse limiar regulatório, sinalizando que o acesso a tratamentos para diabetes e obesidade pode, com o tempo, deixar de ser privilégio de poucos.
- A expiração da patente da Novo Nordisk em março de 2026 derrubou a barreira que mantinha um único fabricante no controle de um dos medicamentos mais desejados do mundo.
- A corrida para ocupar esse espaço foi imediata, mas não sem tropeços — em abril, a Anvisa rejeitou pedidos de outros laboratórios por documentação incompleta e falhas técnicas.
- A EMS navegou com sucesso pelo caminho abreviado de desenvolvimento exigido pela agência, provando qualidade, segurança e eficácia do Ozivy em múltiplas formulações injetáveis.
- A Novo Nordisk já sente a pressão: reduziu preços do Rybelsus e criou condições especiais para o Wegovy, reconhecendo que sua era de domínio incontestado chegou ao fim.
- O Ozivy ainda não tem preço divulgado nem data de chegada às farmácias, mas a aprovação regulatória é o passo decisivo — o momento em que um mercado fechado se abre oficialmente à concorrência.
A Anvisa aprovou o Ozivy, injeção de semaglutida fabricada pela EMS, tornando-o o primeiro produto brasileiro a entrar no mercado após o vencimento da patente da Novo Nordisk em março de 2026. A decisão representa uma virada na disputa por tratamentos contra diabetes tipo 2 e obesidade — medicamentos que se tornaram fenômenos culturais globais, impulsionados por celebridades, redes sociais e demanda médica real.
A semaglutida é o princípio ativo do Ozempic e do Wegovy, dois produtos que dominaram farmácias e manchetes. Até o início deste ano, a Novo Nordisk detinha exclusividade no Brasil. Com o fim dessa proteção, laboratórios correram para ocupar o espaço — mas nem todos conseguiram. Em abril, a Anvisa rejeitou pedidos de outros fabricantes por falhas técnicas e documentação incompleta. A EMS superou esses obstáculos pelo caminho abreviado de desenvolvimento, que exige comprovação de qualidade, segurança e eficácia mesmo para moléculas já conhecidas. O registro concedido é válido até junho de 2036 e cobre cartuchos de 1,5 ml e 3 ml na concentração de 1,34 mg/ml.
A entrada de novos concorrentes tende a reduzir preços, embora não de imediato. A semaglutida é uma molécula biológica complexa, o que eleva as barreiras regulatórias em comparação com genéricos tradicionais. Ainda assim, o Ministério da Saúde demonstra otimismo quanto à ampliação do acesso. A Novo Nordisk já reagiu: anunciou preços especiais para algumas apresentações do Wegovy e reduziu o valor do Rybelsus. A EMS, por sua vez, ainda não divulgou o preço do Ozivy nem quando ele chegará às prateleiras — mas a aprovação regulatória é o passo que transforma um monopólio em mercado.
Brazil's health regulator has cleared the way for a domestic competitor to enter one of the world's most sought-after drug markets. In late May, Anvisa—the country's pharmaceutical watchdog—approved Ozivy, a semaglutida injection made by EMS, the first Brazilian-manufactured version of the blockbuster medication to reach the market after Novo Nordisk's patent expired three months earlier. The approval marks a turning point in the battle over weight-loss and diabetes treatments that have become cultural phenomena, driving billions in global sales and creating fierce competition among manufacturers.
Semaglutida is the active ingredient in two drugs that have dominated headlines and pharmacy shelves: Ozempic, prescribed for type 2 diabetes, and Wegovy, approved specifically for obesity treatment. Until March 2026, Novo Nordisk held exclusive rights to sell these medications in Brazil. Now that protection has ended, pharmaceutical companies are rushing to capture a slice of a market that has exploded in demand, fueled by celebrities, social media, and genuine medical need. The Ozivy approval signals that the monopoly is over.
The regulatory path EMS took was neither simple nor quick. The company pursued what Anvisa calls an abbreviated development pathway—a route designed for drugs based on already-known active ingredients that still must prove their quality, safety, and effectiveness to regulators. The agency spent months evaluating the submission. In April, Anvisa had rejected several applications from other manufacturers due to incomplete documentation and failure to meet technical standards. Ozivy cleared those hurdles. The approval grants the medication a registration valid until June 2036 and covers multiple formulations: injectable solutions in concentrations of 1.34 mg/ml, available in cartridges of 1.5 ml and 3 ml, each paired with applicator pens and needles.
What happens next could reshape the economics of obesity and diabetes treatment in Brazil. When multiple manufacturers compete for the same patients, prices typically fall—though not immediately. Semaglutida is not a simple chemical compound that can be easily copied as a generic drug. It is a complex biologic molecule, which means each new manufacturer must navigate specific regulatory requirements and demonstrate comparable quality and performance. This creates a higher barrier to entry than traditional generics, but it also means competition will eventually arrive. The Health Ministry has signaled optimism that broader access will follow as more companies enter the field.
Nova Nordisk, sensing the shift, has already begun adjusting its strategy. The company has announced special pricing arrangements for some Wegovy formulations and lowered prices on Rybelsus, another semaglutida product. These moves suggest the company recognizes that its days of unchallenged dominance are ending. EMS, for its part, has not yet disclosed the price of Ozivy or when it will actually appear on pharmacy shelves. The company still must complete commercial and distribution arrangements before the drug reaches consumers. But the regulatory approval is the crucial first step—the moment when a closed market officially opens, and the real competition begins.
Notable Quotes
The Health Ministry believes that entry of new manufacturers will expand access to treatment in the future.— Brazil's Health Ministry (paraphrased from source)
The Hearth Conversation Another angle on the story
Why does it matter that this is the first *Brazilian* version, rather than just another semaglutida from any company?
Because it signals that domestic pharmaceutical manufacturing is capable of competing in high-stakes, complex-molecule markets. It's not just about price—it's about proving Brazil can produce these drugs at scale and quality.
The source mentions this isn't a traditional generic. What's the actual difference?
Semaglutida is a biologic—a protein made through living cells, not synthesized in a beaker. Each manufacturer has to prove their version works identically to the original. That's why the regulatory path is longer and more expensive than copying a simple chemical pill.
So prices won't drop as fast as they would with a regular generic?
Correct. But they will drop. Right now Novo Nordisk has no competition. Once EMS is selling and others follow, the company loses pricing power. Novo Nordisk is already cutting prices on some products—that's them bracing for impact.
The approval is valid until 2036. What happens then?
That's when EMS's registration expires and would need renewal. By then, the market will likely have multiple players, and the landscape will look completely different from today.
Why did Anvisa reject other applications in April if Ozivy got approved?
Documentation and technical proof. Some companies didn't submit complete data or couldn't demonstrate their manufacturing met the standards. Ozivy did the work.
What's the real bottleneck now—regulatory approval or getting it into pharmacies?
Getting it into pharmacies. The hard part is done. Now EMS has to set up distribution, negotiate with pharmacy chains, and decide on pricing. That's a business problem, not a regulatory one.